trending Market Intelligence /marketintelligence/en/news-insights/trending/euyhP2354WCAn81Lo7RTHg2 content esgSubNav
In This List

Medical device maker Silk Road sets price range of Nasdaq IPO

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Medical device maker Silk Road sets price range of Nasdaq IPO

Silk Road Medical Inc. expects to price the IPO of 4,687,500 of its common shares on Nasdaq at between $15 and $17 apiece.

The Sunnyvale, Calif.-based medical-device maker is expected to raise about $75 million in gross proceeds, assuming a per share price of $16. The company has applied to list its common stock on the Nasdaq Global Market under the symbol SILK.

The company intends to use the net proceeds to expand sales force and operations, increase research and development activities, to conduct clinical trials, expand internationally, and for working capital and other general corporate purposes.

Silk Road is focused on developing a treatment called transcarotid artery revascularization for carotid artery disease, one of the leading causes of stroke.

J.P. Morgan Securities LLC, Merrill Lynch Pierce Fenner & Smith Inc., BMO Capital Markets Corp. and Stifel Nicolaus & Co. Inc. are acting as underwriters for the IPO.

Silk Road also granted the underwriters a 30-day option to buy an additional 703,125 shares.